- You are here:
- Home
- >
- Guidelines in Practice
- >
- Volume 16 - Edition 10
News
News – October 2013
NICE announces four new quality standards
|
We are delighted to announce the Guidelines app has won the ‘Directory of the Year’ award at the 2013 PPA Digital Publishing Awards. To download the Guidelines app for FREE, search ‘Guidelines MGP’ on the Google Play or App store.
|
Four new quality standards have been published by NICE with the aim of driving and measuring quality improvements within their specific clinical areas.
Quality Standard (QS) 44 covers the management of atopic eczema in children from birth up to the age of 12 years. While not always recognised as a serious medical condition, atopic eczema can have a significant impact on a child’s quality of life.
The diagnosis and management of lower urinary tract symptoms (LUTS) in men (18 years and older) is covered in QS45. Prevalence of LUTS could be as high as 30% in men over 65 years, indicating a large group who might require treatment.
Quality Standard 46 provides quality statements on the management of twin and triplet pregnancies in the antenatal period. Multiple pregnancy is associated with higher risks for both mother and babies, with maternal mortality associated with multiple births 2.5 times that for singleton births.
Finally, QS47 covers the care of women of reproductive age (including women younger than 18 years) with heavy menstrual bleeding as a result of cyclical ovarian activity or underlying uterine fibroids.
SIGN releases new guidance on the treatment of breast cancer
Breast cancer is the most common form of cancer in women in Scotland, and the second commonest cancer overall after lung cancer. The incidence of breast cancer has risen by approximately 12% in the last 10 years and with new therapies for the treatment of primary breast cancer in continual development, the optimisation of treatment is very important.
SIGN 134, Treatment of primary breast cancer, replaces SIGN 84, Management of breast cancer in women, and provides evidence-based recommendations on treatment of patients with operable early breast cancer. Recommendations within the following areas were highlighted by the guideline development group as key recommendations that should be prioritised for implementation:
- surgery
- radiotherapy
- adjuvant systemic therapy
- adjuvant endocrine therapy
- neoadjuvant systemic therapy
- neoadjuvant endocrine therapy.
SIGN 134 excludes diagnosis, staging, follow up, and management of patients with metastatic disease and the use of complementary therapies and lifestyle management.
News in brief—Clinical Guideline (CG) 171 on Urinary incontinence in women has been published by NICE
The guideline includes recommendations on:
- lifestyle interventions
- physical therapies
- behavioural therapies
- pharmacological treatment
- alternative conservative management options.
News in brief—NICE has written two new accreditation case studies
NICE has written two new accreditation case studies based on the experiences of the UK Standards for Microbiology Investigations and First Databank. They describe how the accreditation process helped to identify where improvements could be made.
www.nice.org.uk/aboutnice/accreditation/casestudies
News in brief—NHS Evidence has published a new Evidence Update on obsessive compulsive disorder
The key points presented in Evidence Update 47 have been determined not to have any potential impact on the recommendations within NICE Clinical Guideline 31, Obsessive compulsive disorder (OCD) and body dysmorphic disorder (BDD). Evidence Updates provide a summary of selected new evidence published since the literature search was last conducted for their associated guidance.
News in brief—In recently published Technology Appraisal (TA) 296, NICE does not recommend crizotinib
NICE does not recommend crizotinib for treating adults with previously treated anaplastic-lymphoma-kinase-positive advanced non-small-cell lung cancer as it does not provide enough benefit to patients to justify its high cost, even when special considerations were applied.TA296 recommends that people currently receiving crizotinib should be able to continue treatment until they and their clinician consider it appropriate to stop.
Please to rate this article, view others comments or make your own.
